Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
 - EconoTimes)
NEW YORK, Jan. 10, 2017 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Agile Therapeutics, Inc. (“Agile Therapeutics” or the “Company”) (NASDAQ:AGRX) in the United States District Court for the District of New Jersey on behalf of purchasers of common stock of Agile Therapeutics between March 9, 2016 and January 3, 2017 (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the Securities Exchange Act of 1934.
According to the Complaint, Defendants failed to disclose: (1) that the Twirla contraceptive patch had an efficacy rating that fell below peer group standards; (2) that over half of patients in its “Secure” Phase 3 Study discontinued the study early; (3) that the Twirla patch therefore allegedly had a slight chance of FDA approval; and (4) that, as a result of the foregoing, Defendants’ statements about Agile’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On January 3, 2017, Agile disclosed statistical information pertaining to its Phase 3 SECURE study analyzing the Company’s combined hormonal contraceptive patch Twirla. The study, which was initiated at the request of the FDA, comes after the FDA rejected Agile’s initial marketing application back in 2013. The Company cited “positive top-line results” in the study, yet reported an efficacy measure that failed to meet the standard set by other approved contraceptive patches. Additionally, 51.4% of subjects opted to discontinue the study.
On this news, Agile stock fell nearly 64% during intraday trading on January 4, 2017.
If you wish to serve as lead plaintiff, you must move the Court no later than March 7, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
